कृपया अन्य खोज का प्रयास करें
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostatic hyperplasia; DKF-340, a nonsteroidal anti-inflammatory drugs; DKM-415, indicated for synovial fluid replacement; DKF-334 and DKF-335 to treat osteoporosis; and DKF-363, for treatment of respiratory inflammation. In addition, the company develops DKB-119 and DKM-410, a biomaterial for tissue restoration; as well as develops new drugs for obesity and diabetes that is in preclinical studies. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. The company was founded in 1968 and is headquartered in Seoul, South Korea.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Gi-Beom Kwon | 57 | - | Vice Chairperson |
Min-Gu Lee | 57 | - | Outside Director |
Young-Wook Lee | 71 | - | CEO, President & Director |
Jae-Sung Gu | 62 | - | Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है